Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
2002 · PubMed · 617 citations
F
F. Michael Yakes
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
72
Papers
7.9K
Citations
22
h-index
25
i10-index
F. Michael Yakes is an academic researcher. The author has contributed to research in topics: PI3K/AKT/mTOR signaling in cancer & Liver physiology and pathology & Cancer Mechanisms and Therapy. The author has an h-index of 22, co-authored 62 publications.
Papers by this author
worksEpidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
2001 · PubMed · 549 citations
ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
2001 · PubMed · 180 citations
HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer
2002 · Seminars in Oncology · 82 citations
https://doi.org/10.1016/s0093-7754(02)70121-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat